Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate. Patients often relapse after receiving initial therapy, making it especially challenging for clinicians to keep this destructive disease in check. In a new study, researchers from MIT, in collaboration with researchers involved in the PETAL consortium at Massachusetts General Hospital, identified a practical and powerful prognostic marker that could help clinicians identify high-risk patients early, and potentially tailor treatment strategies to improve survival. The team found that, when patients relapse within 12 months of initial therapy, their chances of survival decline dramatically. For these patients, targeted therapies might improve their chances for survival, compared to traditional chemotherapy, the researchers say. According to their analysis, which used data collected from thousands of patients all over the world, the finding holds true across patient...
learn more
